Patents by Inventor Phong H. Vu
Phong H. Vu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11197858Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: January 27, 2020Date of Patent: December 14, 2021Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Publication number: 20200230137Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: January 27, 2020Publication date: July 23, 2020Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Patent number: 10543212Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: March 23, 2018Date of Patent: January 28, 2020Assignee: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
-
Publication number: 20190224190Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: ApplicationFiled: April 3, 2019Publication date: July 25, 2019Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Patent number: 10307414Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: GrantFiled: September 27, 2017Date of Patent: June 4, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Publication number: 20180280389Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: March 23, 2018Publication date: October 4, 2018Applicant: Cardurion Pharmaceuticals, LLCInventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
-
Patent number: 9994547Abstract: Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.Type: GrantFiled: October 2, 2015Date of Patent: June 12, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Simone Bigi, Walter Keung, Steve Swann, Phong H. Vu, Steven John Woodhead, Anthony R. Gangloff
-
Publication number: 20180015083Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: ApplicationFiled: September 27, 2017Publication date: January 18, 2018Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Publication number: 20170313675Abstract: Disclosed are compounds of formula 1: which are useful as inhibitors of TBK1. Also disclosed are pharmaceutical compositions which contain the compounds, methods for treatment of conditions associated with TBK1, and processes for making the compounds and intermediates thereof.Type: ApplicationFiled: October 2, 2015Publication date: November 2, 2017Inventors: Simone Bigi, Walter Keung, Steve Swann, Phong H. Vu, Steven John Woodhead, Anthony R. Gangloff
-
Patent number: 9801872Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: GrantFiled: June 29, 2016Date of Patent: October 31, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Publication number: 20160310483Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: ApplicationFiled: June 29, 2016Publication date: October 27, 2016Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Patent number: 9402841Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: GrantFiled: March 10, 2014Date of Patent: August 2, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Publication number: 20140256734Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
-
Patent number: 8669249Abstract: Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.Type: GrantFiled: March 26, 2010Date of Patent: March 11, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Jason W. Brown, Anthony R. Gangloff, Andrew John Jennings, Phong H. Vu
-
Publication number: 20120094992Abstract: Compounds of the following formula are provided for use in inhibiting Poly (ADP-ribose) Polymerase (PARP): wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds.Type: ApplicationFiled: March 26, 2010Publication date: April 19, 2012Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Jason W. Brown, Anthony R. Gangloff, Andrew John Jennings, Phong H. Vu
-
Patent number: 7642275Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formulae: wherein the variables are as defined herein.Type: GrantFiled: December 16, 2005Date of Patent: January 5, 2010Assignee: Takeda San Diego, Inc.Inventors: Jerome C. Bressi, Jason W. Brown, Robert J. Skene, Jeffrey A. Stafford, Phong H. Vu, Anthony R. Gangloff, Andrew J. Jennings, Stephen W. Kaldor
-
Patent number: 7642253Abstract: Compounds, pharmaceutical compositions, kits and methods useful for inhibiting HDAC, thereby treating a disease state for which HDAC possess activity that contributes to the pathology and/or symptomology of the disease state. The compound is selected from the group consisting of: wherein the variables are as defined herein.Type: GrantFiled: May 10, 2006Date of Patent: January 5, 2010Assignee: Takeda San Diego, Inc.Inventors: Jerome C. Bressi, Jason W. Brown, Anthony R. Gangloff, Jeffrey A. Stafford, Phong H. Vu
-
Patent number: 7399884Abstract: Histone deacetylase inhibitors and uses thereof are provided that have the general formula wherein R1, R2, R3 and R4 are each independently selected from the group consisting of hydrogen, a substituted or unsubstituted straight chained C1-12 alkyl, C2-12 aminoalkyl or C2-12 oxaalkyl, and a substituted and unsubstituted 3, 4, 5, 6, 7 or 8 membered ring, with the proviso that R3 and R4 are not both hydrogen; R5 is selected from the group consisting of a carbonyl, a substituted or unsubstituted C1-3 alkyl, a substituted or unsubstituted —C1-3 alkyl-C(O), a substituted or unsubstituted —C(O)—C1-3 alkyl, and a substituted or unsubstituted —C(O)C(O)C1-3 alkyl; M is a substituent capable of complexing with a protein metal ion; and L is a substituent comprising a chain of 3-12 atoms connecting the M substituent to the carbon atom alpha to the L substituent.Type: GrantFiled: November 7, 2006Date of Patent: July 15, 2008Assignee: Takeda San Diego, Inc.Inventors: Jerome C. Bressi, Sheldon X. Cao, Jeffrey A. Stafford, Phong H. Vu
-
Patent number: 7381825Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.Type: GrantFiled: March 17, 2004Date of Patent: June 3, 2008Assignee: Takeda San Diego, Inc.Inventors: Jerome C. Bressi, Jason W. Brown, Sheldon X. Cao, Anthony R. Gangloff, Andrew J. Jennings, Jeffrey A. Stafford, Phong H. Vu, Xiao-Yi Xiao
-
Patent number: 7375228Abstract: Compounds that may be used to inhibit histone deacetylase having the formula Z-Q-L-M or Z-L-M wherein M is a substituent capable of complexing with a deacetylase catalytic site and/or a metal ion; L is a substituent providing between 0-10 atoms separation between the M substituent and the remainder of the compound; and Z and Q are as defined herein.Type: GrantFiled: March 17, 2004Date of Patent: May 20, 2008Assignee: Takeda San Diego, Inc.Inventors: Jerome C. Bressi, Jason W. Brown, Sheldon X. Cao, Anthony R. Gangloff, Andrew J. Jennings, Jeffrey A. Stafford, Phong H. Vu, Xiao-Yi Xiao